SARC 012: A Randomized, Double-Blinded, Placebo-Controlled, Multi-Institutional, Phase II.5 Study of AZD0530, a Selective Src Kinase Inhibitor, In Patients with Recurrent Osteosarcoma Localized to the Lung

Why are we doing this research?

The purpose of this study is to determine how long patients who undergo complete surgical removal of recurrent osteosarcoma in the lung will remain free of cancer after taking Saracatinib compared to patients taking placebo (a sugar pill).

Who can participate?

Ages Available for Study: 15 years to 74 years

Ages

  • From 15 to 74 years old

Conditions

  • Adult Studies
  • Cancer - Musculoskeletal Tumors

Gender

  • Female
  • Male

Contact

Cincinnati Children’s Hospital Medical Center
Cancer and Blood Diseases Institute
3333 Burnet Ave., Cincinnati, OH 45229-3039
Phone: 513-636-8790
cancer@cchmc.org